Literature DB >> 11809679

A homozygous germ-line mutation in the human MSH2 gene predisposes to hematological malignancy and multiple café-au-lait spots.

Darcy Whiteside1, Ross McLeod, Gail Graham, Jamie L Steckley, Karen Booth, Martin J Somerville, Susan E Andrew.   

Abstract

Individuals with a germ-line mutation in one of the DNA mismatch repair (MMR) genes are at significant risk for colorectal cancer and other tumors. Three families have previously been reported with individuals homozygous for mutations in the MMR gene MLH1 that are predicted to compromise MMR. These individuals develop hematological malignancies and/or neurofibromatosis type 1 at an early age. Here, in an individual, we demonstrate that a homozygous novel mutation in the MMR gene MSH2 is associated with leukemia and multiple café-au-lait spots, a feature of neurofibromatosis type 1. Because the hematological malignancies observed in the individuals homozygous for the loss of MMR are reflective of the lymphomas seen in mice lacking MMR, the mice may provide a useful model for human neoplasia.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11809679

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  39 in total

1.  Early onset brain tumor and lymphoma in MSH2-deficient children.

Authors:  Gaëlle Bougeard; Françoise Charbonnier; Alexandre Moerman; Cosette Martin; Marie M Ruchoux; Nathalie Drouot; Thierry Frébourg
Journal:  Am J Hum Genet       Date:  2003-01       Impact factor: 11.025

2.  Analysis of MYH Tyr165Cys and Gly382Asp variants in childhood leukemias.

Authors:  Cemaliye Boylu Akyerli; Uğur Ozbek; Müge Aydin-Sayitoğlu; Sema Sirma; Tayfun Ozçelik
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-13       Impact factor: 4.553

3.  Constitutional mismatch repair-deficiency syndrome.

Authors:  Katharina Wimmer; Christian P Kratz
Journal:  Haematologica       Date:  2010-05       Impact factor: 9.941

Review 4.  Syndrome of early onset colon cancers, hematologic malignancies & features of neurofibromatosis in HNPCC families with homozygous mismatch repair gene mutations.

Authors:  Prathap Bandipalliam
Journal:  Fam Cancer       Date:  2005       Impact factor: 2.375

5.  Humans accumulate microsatellite instability with acquired loss of MLH1 protein in hematopoietic stem and progenitor cells as a function of age.

Authors:  Jonathan Kenyon; Pingfu Fu; Karen Lingas; Emily Thomas; Anshul Saurastri; Gabriela Santos Guasch; David Wald; Stanton L Gerson
Journal:  Blood       Date:  2012-06-26       Impact factor: 22.113

6.  Novel PMS2 pseudogenes can conceal recessive mutations causing a distinctive childhood cancer syndrome.

Authors:  Michel De Vos; Bruce E Hayward; Susan Picton; Eamonn Sheridan; David T Bonthron
Journal:  Am J Hum Genet       Date:  2004-04-07       Impact factor: 11.025

7.  Compound heterozygosity for two MSH2 mutations suggests mild consequences of the initiation codon variant c.1A>G of MSH2.

Authors:  Carolien M Kets; Nicoline Hoogerbrugge; Joannes H J M van Krieken; Monique Goossens; Han G Brunner; Marjolijn J L Ligtenberg
Journal:  Eur J Hum Genet       Date:  2008-09-10       Impact factor: 4.246

8.  Biallelic mutation of MSH2 in primary human cells is associated with sensitivity to irradiation and altered RAD51 foci kinetics.

Authors:  J Barwell; L Pangon; S Hodgson; A Georgiou; I Kesterton; T Slade; M Taylor; S J Payne; H Brinkman; J Smythe; N J Sebire; E Solomon; Z Docherty; R Camplejohn; T Homfray; J R Morris
Journal:  J Med Genet       Date:  2007-05-04       Impact factor: 6.318

Review 9.  Genotype to phenotype: analyzing the effects of inherited mutations in colorectal cancer families.

Authors:  Christopher D Heinen
Journal:  Mutat Res       Date:  2009-09-17       Impact factor: 2.433

10.  Thyroid cancer in a patient with a germline MSH2 mutation. Case report and review of the Lynch syndrome expanding tumour spectrum.

Authors:  Rein P Stulp; Johanna C Herkert; Arend Karrenbeld; Bart Mol; Yvonne J Vos; Rolf H Sijmons
Journal:  Hered Cancer Clin Pract       Date:  2008-02-15       Impact factor: 2.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.